Avecho Biotechnology (ASX:AVE) has locked in 244 patients for its Phase III insomnia interim analysis, with the late June 2026 readout now a hard date.
21
Stocks in Spotlight
View all →-
-
AI Stocks · Semiconductor stocks SanDisk (NASDAQ:SNDK) The Sell Case Behind a 3,300% AI Memory Rally May 21, 2026 -
AI Stocks · Blue Chip Stocks Life360 (ASX:360): Ad Revenue Jumped 329%, So Why Did the Stock Fall? May 12, 2026
